Avoro Capital Advisors Reduces $95M in Atrium Therapeutics, Inc. ($RNA)

Avoro Capital Advisors has exited its position in Atrium Therapeutics, Inc. (NasdaqGS: RNA) by selling all 7.65 million shares it previously held. This move was detailed in the fund's latest 13F filing with the SEC, showing a complete 100% reduction in its holdings as of the reporting period.

What Changed in Avoro Capital Advisors' Atrium Therapeutics Position

Avoro Capital Advisors completely cut its position in Atrium Therapeutics, selling all 7,645,000 shares it previously held. This marks a 100% decrease in its stake, reflecting a strategic decision to exit the investment entirely.

Other Institutional Activity in Atrium Therapeutics

Other institutional investors have also been active in Atrium Therapeutics. Price T Rowe Associates Inc. increased its holdings by 1,410,322 shares, reaching a total of 1,553,210 shares valued at approximately $20.77 million. Conversely, BlackRock, Inc. reduced its position by 11,645,510 shares, ending with 1,205,291 shares worth about $16.11 million. RA Capital Management, L.P. also trimmed its stake by 7,776,929 shares, holding 864,102 shares valued at $11.55 million. Meanwhile, Vanguard Capital Management LLC and TIG Advisors, LLC both initiated positions, acquiring 626,869 and 607,552 shares, respectively.

Atrium Therapeutics Stock Snapshot

Shares of Atrium Therapeutics (NasdaqGS: RNA) traded near $12.37 recently. The company has a market cap of $211.6 million. Although it isn't profitable, with a negative forward P/E, it has a 52-week low of $11.40 and a high of $16.77. Its 50-day moving average is $13.08, and the 200-day moving average is $13.39. Atrium maintains strong liquidity with a current ratio of 13.04 and a quick ratio of 12.91, while its debt-to-equity ratio stands at 1.15.

Recent Earnings

Atrium Therapeutics reported revenue of $36.68 million, showing a growth rate of 11.5%. However, the company faced a net margin of -159.99%, indicating significant losses. Its next earnings report is expected on May 11, 2026.

Insider Buying and Selling at Atrium Therapeutics, Inc.

Several insiders at Atrium Therapeutics made significant stock purchases on April 20, 2026. Chief Strategy Officer Rocio Martin Hoyos acquired 60,000 shares, while CEO Kathleen Gallagher bought 102,500 shares. Chief Medical Officer Steven George Hughes, Chief Corporate Affairs Officer Stephanie Kenney, and CFO Brendan Winslow each purchased 30,000 shares. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On May 15, 2026, Leerink Partners initiated coverage on Atrium Therapeutics with a 'buy' rating and a $25 price target. Similarly, Wells Fargo began coverage on March 11, 2026, with the same rating and target. The consensus among analysts is a 'buy' recommendation, with a mean target price of $25 based on two opinions.

About Atrium Therapeutics

Atrium Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing RNA therapeutics aimed at treating cardiomyopathies. The company's leading candidates include ATR 1072 and ATR 1086, both siRNA-based therapies targeting specific genetic conditions affecting the heart. Founded in 2025, Atrium is led by CEO Kathleen P. Gallagher.

Bottom Line

Avoro Capital Advisors' decision to sell its entire stake in Atrium Therapeutics reflects a significant shift in its investment strategy. Investors and analysts continue to watch Atrium closely as it pursues innovative treatments in the biopharmaceutical field. It's important to remember that 13F filings are backward-looking and may not represent current positions.